In contrast, we found a decreased percentage of the early-differentiated CD8+ subset (p = 0.023) and an increased percentage of the late-differentiated CD8+ subset (p = 0.002) in CMV-seropositive MS patients compared to CMV-seronegative MS patients (Figure 2I and Figure 2J, respectively). The gene discussed is CD8A; the disease is myeloid sarcoma.